查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597837

TNF 抑制劑市場：按產品、按應用分類 - 2025-2030 年全球預測

TNF Inhibitors Market by Product (Biosimilars, Cimzia, Enbrel), Application (Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年TNF抑制劑市值為338.4億美元，預計2024年將達到361.5億美元，複合年成長率為6.92%，到2030年將達到540.6億美元。

TNF 抑制劑（腫瘤壞死因子抑制劑）是一種用於抑制發炎和阻止自體免疫疾病（如類風濕性關節炎、乾癬和發炎性腸道疾病）疾病進展的藥物。其應用既具有治療性又具有預防性，透過抑制發炎細胞激素TNF 來緩解患者的症狀。對 TNF 抑制劑的需求源於其在慢性發炎和自體免疫疾病治療中的重要作用，這些疾病可能嚴重影響生活品質和生產力。 TNF 抑制劑的應用主要包括專門治療這些疾病的製藥公司和醫療保健提供者，最終用途包括醫院、診所和居家照護機構。影響市場的關鍵成長要素包括自體免疫疾病盛行率的上升、醫療保健支出的增加以及促進新配方開發的生物技術的發展。此外，生物療法的廣泛接受為市場擴張提供了新的機會。然而，高成本、生物相似藥競爭和嚴格的監管要求等挑戰構成了主要障礙。為了緩解這些障礙，人們越來越關注透過口服生技藥品和奈米顆粒遞送等創新技術來改善遞送機制並減少副作用。最新的商機包括透過先進的基因研究和利用人工智慧的藥物發現來促進個人化醫療和提高治療效果。公司還可以探索向新興市場進行地理擴張，這些市場的患者人數不斷成長，但治療選擇有限。此外，可以透過加強病患教育和促進醫療保險覆蓋合作來提高市場滲透率。儘管面臨監管限制和競爭壓力等挑戰，但由於專注於未滿足的醫療需求的策略創新，TNF抑制劑市場仍具有巨大的成長潛力。透過客製化解決方案來解決特定客戶和患者的挑戰，公司可以在這個動態的市場格局中建立一個引人注目的地位。

主要市場統計
基準年[2023] 338.4億美元
預測年份 [2024] 361.5億美元
預測年份 [2030] 540.6億美元
複合年成長率（%） 6.92%

市場動態：揭示快速發展的 TNF 抑制劑市場的關鍵市場洞察

供需的動態交互作用正在改變 TNF 抑制劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 自體免疫疾病盛行率增加
    • 醫療支出的增加和診斷技術的發展
  • 市場限制因素
    • 與使用 TNF 抑制劑相關的不良健康影響和感染風險
  • 市場機會
    • 生物技術的進步、新型和改進的 TNF 抑制劑的開發
    • 擴大癌症等各種疾病治療的應用
  • 市場問題
    • 自體免疫疾病替代治療方案的可用性

波特五力：駕馭 TNF 抑制劑市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 TNF 抑制劑市場的外部影響

外部宏觀環境因素在塑造 TNF 抑制劑市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解TNF抑制劑市場的競爭格局

對 TNF 抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：TNF 抑制劑市場供應商的績效評估

FPNV定位矩陣是評估TNF抑制劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製 TNF 抑制劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對 TNF 抑制劑市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 自體免疫疾病增加
      • 醫療費用的增加和診斷技術的發展
    • 抑制因素
      • 與使用 TNF 抑制劑相關的不良健康影響和感染風險
    • 機會
      • 生物技術的進步以及新型和改進的 TNF 抑制劑的開發
      • 擴大在癌症等各種疾病治療的應用
    • 任務
      • 自體免疫疾病替代治療方案的可用性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 TNF 抑制劑市場：依產品

  • 介紹
  • 生物相似藥
  • Cimzia
  • Enbrel
  • Humira
  • Remicade
  • 辛波尼/辛波尼亞裡亞

第7章 TNF 抑制劑市場：依應用分類

  • 介紹
  • 僵直性脊椎炎
  • 克隆氏症
  • 化膿性汗腺炎
  • 幼年特發性關節炎
  • 乾癬
  • 乾癬性關節炎
  • 類風濕性關節炎
  • 潰瘍性大腸炎

第8章美洲TNF抑制劑市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太TNF抑制劑市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲TNF抑制劑市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt. Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Reliance Life Sciences
  • Roche Products India Pvt Ltd.
  • Samsung Bioepis NL BV
  • Sanofi SA
  • Torrent Pharmaceuticals Ltd.
  • UCB Inc.
Product Code: MRR-2A0283E255AF

The TNF Inhibitors Market was valued at USD 33.84 billion in 2023, expected to reach USD 36.15 billion in 2024, and is projected to grow at a CAGR of 6.92%, to USD 54.06 billion by 2030.

TNF inhibitors, or tumor necrosis factor inhibitors, are a class of medications used to reduce inflammation and halt disease progression in autoimmune conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Their scope encompasses both therapeutic and prophylactic applications, providing relief to patients by inhibiting the pro-inflammatory cytokine TNF. The necessity of TNF inhibitors stems from their critical role in managing chronic inflammatory and autoimmune disorders that can severely impact the quality of life and productivity. The application of TNF inhibitors primarily spans pharmaceutical companies and healthcare providers specializing in the treatment of these ailments, with an end-use scope including hospitals, clinics, and home care settings. Key growth factors influencing the market include the rising prevalence of autoimmune diseases, increasing healthcare expenditure, and advancements in biotechnology facilitating the development of novel formulations. Furthermore, a broader acceptance of biological therapies has opened up new potential avenues for market expansion. However, challenges such as high costs, biosimilar competition, and stringent regulatory requirements pose significant barriers. To mitigate these obstacles, research is increasingly focusing on improving delivery mechanisms and reducing side effects through innovations like oral biologics and nanoparticle-delivered TNF inhibitors. The latest opportunities include harnessing advanced genetic research and AI-driven drug discovery to foster personalized medicine, enhancing treatment efficacy. Companies can also explore geographic expansion into emerging markets where the patient pool is expanding, but treatment options are limited. Moreover, bolstering patient education and fostering collaborations for health insurance coverage could enhance market penetration. Despite challenges from regulatory constraints and competitive pressures, the TNF inhibitors market offers substantial potential for growth through strategic innovation and a focus on unmet medical needs. By tailoring solutions that address specific customer and patient challenges, businesses can position themselves compellingly in this dynamic market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 33.84 billion
Estimated Year [2024] USD 36.15 billion
Forecast Year [2030] USD 54.06 billion
CAGR (%) 6.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving TNF Inhibitors Market

The TNF Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of autoimmune diseases
    • Increasing healthcare expenditure and development in diagnostic techniques
  • Market Restraints
    • Adverse health effects and risk of infections associated with the use of TNF inhibitors
  • Market Opportunities
    • Advancements in biotechnology and development of new and improved TNF inhibitors
    • Growing application in treatment of diverse medical conditions such as cancer
  • Market Challenges
    • Availability of alternative treatment options for autoimmune disease

Porter's Five Forces: A Strategic Tool for Navigating the TNF Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the TNF Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the TNF Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the TNF Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the TNF Inhibitors Market

A detailed market share analysis in the TNF Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the TNF Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the TNF Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the TNF Inhibitors Market

A strategic analysis of the TNF Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the TNF Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkem Laboratories Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cadila Healthcare Ltd., Cipla Ltd., Dr Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Janssen Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin Ltd., Macleods Pharmaceuticals Pvt. Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited, Reliance Life Sciences, Roche Products India Pvt Ltd., Samsung Bioepis NL B.V., Sanofi S.A., Torrent Pharmaceuticals Ltd., and UCB Inc..

Market Segmentation & Coverage

This research report categorizes the TNF Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biosimilars, Cimzia, Enbrel, Humira, Remicade, and Simponi/Simponi Aria.
  • Based on Application, market is studied across Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of autoimmune diseases
      • 5.1.1.2. Increasing healthcare expenditure and development in diagnostic techniques
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health effects and risk of infections associated with the use of TNF inhibitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in biotechnology and development of new and improved TNF inhibitors
      • 5.1.3.2. Growing application in treatment of diverse medical conditions such as cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options for autoimmune disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. TNF Inhibitors Market, by Product

  • 6.1. Introduction
  • 6.2. Biosimilars
  • 6.3. Cimzia
  • 6.4. Enbrel
  • 6.5. Humira
  • 6.6. Remicade
  • 6.7. Simponi/Simponi Aria

7. TNF Inhibitors Market, by Application

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Crohn's Disease
  • 7.4. Hidradenitis Suppurativa
  • 7.5. Juvenile Idiopathic Arthritis
  • 7.6. Psoriasis
  • 7.7. Psoriatic Arthritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Ulcerative Colitis

8. Americas TNF Inhibitors Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific TNF Inhibitors Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa TNF Inhibitors Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkem Laboratories Ltd.
  • 3. Amgen Inc.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Bristol Myers Squibb
  • 6. Cadila Healthcare Ltd.
  • 7. Cipla Ltd.
  • 8. Dr Reddy's Laboratories Ltd.
  • 9. Emcure Pharmaceuticals Ltd.
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Intas Pharmaceuticals Ltd.
  • 12. Janssen Pharmaceuticals
  • 13. Johnson & Johnson Services, Inc.
  • 14. Lupin Ltd.
  • 15. Macleods Pharmaceuticals Pvt. Ltd.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Ranbaxy Laboratories Limited
  • 20. Reliance Life Sciences
  • 21. Roche Products India Pvt Ltd.
  • 22. Samsung Bioepis NL B.V.
  • 23. Sanofi S.A.
  • 24. Torrent Pharmaceuticals Ltd.
  • 25. UCB Inc.

LIST OF FIGURES

  • FIGURE 1. TNF INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. TNF INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TNF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TNF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TNF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TNF INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TNF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TNF INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TNF INHIBITORS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TNF INHIBITORS MARKET SIZE, BY ENBREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TNF INHIBITORS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TNF INHIBITORS MARKET SIZE, BY REMICADE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TNF INHIBITORS MARKET SIZE, BY SIMPONI/SIMPONI ARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TNF INHIBITORS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TNF INHIBITORS MARKET SIZE, BY HIDRADENITIS SUPPURATIVA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TNF INHIBITORS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TNF INHIBITORS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TNF INHIBITORS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDONESIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. INDONESIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. JAPAN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. JAPAN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MALAYSIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. MALAYSIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. PHILIPPINES TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. PHILIPPINES TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SINGAPORE TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. SINGAPORE TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. SOUTH KOREA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. SOUTH KOREA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. TAIWAN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. TAIWAN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. THAILAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. THAILAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. VIETNAM TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. VIETNAM TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. DENMARK TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. DENMARK TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. EGYPT TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. EGYPT TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FINLAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. FINLAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. FRANCE TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. FRANCE TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. GERMANY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. GERMANY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ISRAEL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. ISRAEL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ITALY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. ITALY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NETHERLANDS TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. NETHERLANDS TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NIGERIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. NIGERIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. NORWAY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. NORWAY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. POLAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. POLAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. QATAR TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. QATAR TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. RUSSIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. RUSSIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SAUDI ARABIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SAUDI ARABIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH AFRICA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH AFRICA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SPAIN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. SPAIN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWEDEN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. SWEDEN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SWITZERLAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. SWITZERLAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. TURKEY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. TURKEY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED ARAB EMIRATES TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED ARAB EMIRATES TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED KINGDOM TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED KINGDOM TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. TNF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 110. TNF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023